Andersen J B, Jensen N H, Klausen N O
Ugeskr Laeger. 1989 Jul 10;151(28):1820-2.
In a controlled study with random allocation, the effect of doxapram (Dopram), a respiratory stimulant, was evaluated in 25 patients with acute on chronic respiratory failure requiring ventilator support. Eleven patients were allocated to mechanical ventilation and 14 to treatment with doxapram given as a variable rate infusion. In the doxapram group only four were transferred to mechanical ventilation after 1 1/2 to three days of treatment. In these patients, the problem giving rise to the acute exacerbation, was not under control at the time of ventilator intervention. In the remainder of the group, antibiotics, diuretics and bronchodilators had successfully treated the exacerbation. All patients were discharged alive. In the doxapram-treated group duration of hospitalization was nine days compared to 14 days (median values) in the ventilator-treated group. Only minor side-effects from doxapram were observed, and it is concluded that this respiratory stimulant can be used as a primary drug in patients with acute respiratory failure and chronic airflow limitation.
在一项随机分配的对照研究中，对25例需要呼吸机支持的急性慢性呼吸衰竭患者评估了呼吸兴奋剂多沙普仑（多普兰）的效果。11例患者接受机械通气，14例接受多沙普仑可变速率输注治疗。在多沙普仑组中，仅4例在治疗1.5至3天后转为机械通气。在这些患者中，导致急性加重的问题在进行呼吸机干预时未得到控制。在该组其余患者中，抗生素、利尿剂和支气管扩张剂成功治疗了病情加重。所有患者均存活出院。多沙普仑治疗组的住院时间为9天，而呼吸机治疗组为14天（中位数）。仅观察到多沙普仑的轻微副作用，得出的结论是，这种呼吸兴奋剂可作为急性呼吸衰竭和慢性气流受限患者的一线药物。
